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PAcute Myocardial Infarction
Effect of Early, Pre-Hospital Initiation
of High Bolus Dose Tirofiban in Patients
With ST-Segment Elevation Myocardial
Infarction on Short- and Long-Term Clinical Outcome
Jurriën M. ten Berg, MD, PHD,* Arnoud W. J. van ’t Hof, MD, PHD,† Thorsten Dill, MD, PHD,‡
Ton Heestermans, MD,† Jochem W. van Werkum, MD, PHD,* Arend Mosterd, MD, PHD,§#**
Gert van Houwelingen, MD, Petra C. Koopmans, MSC,¶ Pieter R. Stella, MD, PHD,**
Eric Boersma, MSC, PHD,†† Christian Hamm, MD, PHD,‡ on behalf of the On-TIME 2 Study Group
Nieuwegein, Zwolle, Amersfoort, Enschede, Utrecht, and Rotterdam, the Netherlands;
and Bad Nauheim, Germany
Objectives The purpose of this trial was to study the effect of a high bolus dose (HBD) of tirofiban on clinical outcome in
patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
(STEMI).
Background The On-TIME 2 (Ongoing Tirofiban In Myocardial infarction Evaluation 2) placebo-controlled, double-blind, ran-
domized trial showed that early administration of HBD tirofiban in the ambulance improves ST-segment resolu-
tion in patients with STEMI undergoing primary percutaneous coronary intervention. The effect of early tirofiban
treatment on clinical outcome is unclear.
Methods The On-TIME 2 trial consisted of 2 phases: an open-label phase, followed by a double-blind, placebo-controlled
phase. STEMI patients were randomized to either HBD tirofiban or no tirofiban (phase 1) or placebo (phase 2) in
addition to aspirin, heparin, and high-dose clopidogrel. The protocol pre-specified a pooled analysis of the 2
study phases to assess the incidence of major adverse cardiac events at the 30-day follow-up and on total mor-
tality at the 1-year follow-up.
Results During a 3-year period, 1,398 patients were randomized, 414 in phase 1 and 984 in phase 2. Major adverse
cardiac events at 30 days were significantly reduced (5.8% vs. 8.6%, p  0.043). There was a strong trend to-
ward a decrease in mortality (2.2% vs. 4.1%, p  0.051) in patients who were randomized to tirofiban pre-
treatment, which was maintained during the 1-year follow-up (3.7% vs. 5.8%, p  0.08). No clinically relevant
difference in bleeding was observed.
Conclusions Early, pre-hospital initiation of HBD tirofiban, in addition to high-dose clopidogrel, improves the clinical outcome
after primary percutaneous coronary intervention in patients with STEMI. (Ongoing 2b/3a inhibition In Myocar-
dial infarction Evaluation; ISRCTN06195297) (J Am Coll Cardiol 2010;55:2446–55) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.091i
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June 1, 2010:2446–55 High-Dose Tirofiban in STEMIhe blood flow in the infarct-related vessel (4,5). Transporting
atients to an intervention center, however, inevitably leads to
delay in initiation of the pPCI and thus prolongs ischemic
ime. The early initiation of antithrombotic treatment for
TEMI patients before pPCI potentially opens the occluded
essel during transportation and reduces periprocedural throm-
otic complications (6). Glycoprotein (GP) IIb/IIIa receptor
lockers are very effective inhibitors of platelet aggregation,
ven when administered in addition to aspirin and clopidogrel
7) and have been shown to reduce thrombotic complications
n patients undergoing percutaneous coronary intervention
PCI) (8). In our randomized, double-blind, placebo-
ontrolled On-TIME 2 (Ongoing Tirofiban In Myocardial
See page 2456
nfarction Evaluation 2) trial, we recently demonstrated that
he GP IIb/IIIa receptor blocker tirofiban, when given in the
mbulance, resulted in an improvement in ST-segment reso-
ution as a marker for myocardial perfusion in patients with
TEMI undergoing pPCI (9). However, this trial did not have
ufficient power to study the effect of a high bolus dose (HBD)
f tirofiban on clinical outcome. In this article, we present a
re-specified pooled analysis of the placebo-controlled study
hase and the open-label study phase to investigate the effect of
arly administration of HBD tirofiban on clinical outcome.
his larger sample size also enabled us to study subgroups of
atients who would most likely benefit from early administra-
ion of HBD tirofiban.
ethods
he On-TIME 2 trial was a multicenter, prospective,
andomized clinical trial. The study consisted of 2 phases: a
andomized, open-label phase (phase 1) and a placebo-
ontrolled, randomized, double-blind phase (phase 2). The
ationale and design of the study were described previously
10). In brief, the study population consisted of patients
ith STEMI who were candidates for pPCI treatment.
ligible patients were men and women 21 to 85 years of age
ith symptoms of acute myocardial infarction (MI) for30
in but 24 h, and an ST-segment elevation of 1 mV in
adjacent electrocardiogram leads. Exclusion criteria were
nown severe renal dysfunction, therapy-resistant cardio-
enic shock, persistent severe hypertension, and an in-
reased risk of bleeding. Also excluded were patients with a
eft bundle branch block and patients with a life expectancy
f 1 year.
Written informed consent was obtained by an intensive
are nurse in the ambulance or, in a minority of the patients,
y a physician in the referral center. The study protocol was
pproved by all local ethics committees involved.
Patients were randomly assigned to pre-hospital treat-
ent with tirofiban (25-g/kg bolus and 0.15-g/kg/min
aintenance infusion) or no tirofiban (phase 1), or placebophase 2). Each participating ambulance or referral center eas supplied with sealed study kits
n blocks of 4, containing either
pen-label tirofiban or saline so-
ution vials (phase 1) or blinded
tudy medication (phase 2). The
tudy flowchart is presented in
igure 1. In the ambulance or
eferral center, all patients also
eceived a bolus of unfractionated
eparin (5,000 IU) intravenously,
ogether with aspirin 500 mg (As-
egic) intravenously and an oral
00-mg loading dose of clopi-
ogrel. Before pPCI, an additional
,500 IE unfractionated heparin
as only administered if the acti-
ated clotting time was 200 s.
Coronary angiography and PCI
ere performed according to each
nstitution’s guidelines and stan-
ards. During or after pPCI, bail-
ut tirofiban could be adminis-
ered for the following indications: decrement in
hrombolysis In Myocardial Infarction (TIMI) flow grade
TIMI flow grades of 0 to 2 or slow reflow), dissection with
ecreased flow, distal embolization, side branch closure,
brupt closure of the culprit vessel, clinical instability, and
rolonged ischemia. Bail-out tirofiban was administered in
HBD (25-g/kg bolus). In the double-blind phase of the
rial, blinded bail-out vials were included in the medication
ox to maintain blinding of the initial treatment assignment
o avoid double-dosing. When a bailout vial was adminis-
ered, the study infusion was replaced by open-label tirofi-
an. In the open-label phase, the doses of bail-out tirofiban
nd the indications for administration were similar to those
n the double-blind phase.
The key primary end point of this pooled analysis was the
ncidence of major adverse cardiac events (MACE), as
efined by the composite of death, recurrent MI, or urgent
arget vessel revascularization at the 30-day follow-up. The
econdary end point was total mortality at the 1-year
ollow-up. A blinded independent Clinical Endpoint Com-
ittee adjudicated all clinical end points. Death was defined
s all-cause mortality. Recurrent MI was defined as a new
ncrease of creatine kinase, myocardial bound 3 times the
pper limit of normal present in 2 separate blood samples
nd accompanied by chest pain and/or changes on the
lectrocardiogram. Early recurrent MI was defined as a
ecrease in creatine kinase, myocardial bound of at least
0% of the upper limit of normal from a previous peak
oncentration to a valley, followed by a new increase with a
alue above the sum of the preceding valley and 3 times the
pper limit of normal. Urgent target vessel revascularization
uring the hospitalization period was defined as a new
Abbreviations
and Acronyms
CI  confidence interval
GP  glycoprotein
HBD  high bolus dose
IQR  interquartile range
MACE  major adverse
cardiac events
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
pPCI  primary
percutaneous coronary
intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionpisode of ischemic signs or symptoms at rest, with docu-
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High-Dose Tirofiban in STEMI June 1, 2010:2446–55entation of a new ST-segment shift 0.05 mV (0.5 mm)
n a 12-lead electrocardiogram that necessitated an un-
lanned coronary intervention or a coronary artery bypass
raft of the infarct-related vessel.
The safety end points included the occurrence of a
emorrhage, transfusions, stroke, thrombocytopenia, and
erious adverse events. Bleeding was defined according to
he TIMI criteria (11). Major bleeding was defined as
linical overt signs of hemorrhage associated with a decrease
n hemoglobin of 5 g/dl (or when hemoglobin assessment
s not available, a decrease in hematocrit of 15%). For
atients undergoing coronary artery bypass graft surgery, the
ate of surgical re-exploration for bleeding and the post-
perative volume of blood loss were also evaluated.
Follow-up information was derived from visits to the
utpatient clinic or from telephone contact at the 30-day
ollow-up and at the 1-year follow-up.
tatistical analysis. The pooled analysis of the 2 study
hases was pre-specified in the final study protocol and
tatistical plan. The effect of pre-hospital HBD tirofiban
as evaluated in pre-specified subgroups of patients. In
ddition, a post hoc analysis was performed for patients who
nderwent pPCI. For continuous variables, such as the time
etween the onset of symptoms and diagnosis, subgroup
nalyses were performed, with the median values as cutoff.
All analyses were performed according to the intention-
o-treat principle. Categorical variables were analyzed with
he chi-square test or the Fisher exact test, ordinal categor-
Figure 1 Study Flowchart of the 2 Phases of the Trial
The open-label phase randomized 414 patients at 2 centers to high-dose tirofiban
984 patients were randomized to high-dose tirofiban or placebo at 24 different cen
heparin, and high-dose clopidogrel. MI  myocardial infarction; On-TIME  Ongoin
TVR  target vessel revascularization.cal variables with the chi-square test for linear trend, and tontinuous variables with the Mann-Whitney U test. We
sed the Breslow-Day test to investigate homogeneity of
dds ratios to determine whether the null hypothesis of
qual odds ratios for different strata should be rejected.
ime-to-event analysis was performed to describe survival
ree from MACEs at 30 days and death after 1 year from the
ate of randomization. Survival was represented by Kaplan-
eier curves. Log-rank tests were used to test the signifi-
ance of difference in survival between tirofiban and pla-
ebo/no tirofiban. SPSS for Windows, version 15 (SPSS
nc., Chicago, Illinois) was used for all the analyses.
esults
uring a 3-year period, 1,398 patients were randomized:
14 patients in the open-label phase (phase 1, June 2004 to
une 2006, 2 participating centers) and 984 patients in the
ouble-blind phase (phase 2, June 2006 to November 2007,
4 participating centers). A flowchart of the study is
resented in Figure 1. There were no relevant differences in
aseline clinical or angiographic characteristics between the
atients in the open-label phase and the patients in the
ouble-blind phase (Table 1). Patients in the open-label
roup had slightly higher mean diastolic blood pressure, but
similar systolic blood pressure; they more often had a
rug-eluting stent placed (33.2% vs. 23.6%, p 0.001), and
he mean stent length was slightly longer. Due to the
ifference in study design, a difference in the use of bail-out
tirofiban. This phase was followed by the double-blind phase in which
In both phases, study medication was given in addition to aspirin, unfractionated
ban In Myocardial infarction Evaluation; PCI  primary coronary intervention;or no
ters.
g Tirofiirofiban was found between the study phases: 41.8% in the
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June 1, 2010:2446–55 High-Dose Tirofiban in STEMIpen-label phase versus 24.2% in the double-blind phase
19.9% in the tirofiban group and 28.5% in the placebo
roup). In both study phases, early HBD tirofiban treat-
ent decreased the extent of residual ST-segment deviation
nd improved ST-segment resolution 1 h after PCI as well
s clinical outcome at 30 days and 1 year compared with
lacebo/no tirofiban treatment (Table 2). After pooling the
pen-label and double-blind study phases on an individual
aseline and Angiographic CharacteristicsTable 1 Baseline and Angiographic Characteristics
Total
(N  1,398)
Placebo/No
(n  6
Baseline characteristics
Age, yrs 61.8 12.0 62.0
Male sex 1,063/1,398 (76.0%) 520/689 (7
BMI, kg/m2 (n  1,202) 26.8 3.8 26.7
Current smoker 649/1,374 (47.2%) 330/677 (4
Anterior infarct location 534/1,242 (43.0%) 266/618 (4
Diabetes 156/1,394 (11.2%) 73/687 (1
Hypertension 475/1,394 (34.1%) 236/687 (3
Hypercholesterolemia 357/1,390 (25.7%) 171/685 (2
Family history of cardiovascular disease 545/1,363 (40.0%) 266/673 (3
Previous MI 126/1,392 (9.1%) 63/688 (9
Previous PCI 113/1,396 (8.1%) 50/689 (7
Previous CABG 29/1,396 (2.1%) 17/689 (2
Previous CVA 22/1,395 (1.6%) 12/689 (1
Renal failure (GFR 60 ml/min) 212/1,295 (16.4%) 99/633 (1
Inclusion in ambulance 1,343/1,398 (96.1%) 666/689 (9
Blood pressure systolic, mm Hg (n  1,369) 131.8 24.5 131.2
Blood pressure diastolic, mm Hg (n  1,364) 77.9 15.4 77.6
Heart rate, beats/min (n  1,379) 74.9 17.5 75.0
Killip 1 169/1,365 (12.4%) 93/672 (1
Cumulative ST-segment deviation diagnosis
on ECG (n  1,339)
14.4 8.9 14.2
False-positive infarct diagnosis 81/1,398 (5.8%) 40/689 (5
Transportation distance, km,
median (IQR) (n  916)
25 (12–41) 25 (1
Ischemic time, min, median (IQR) 166 (128–246) 166 (1
Time from SO to diagnosis, min,
median (IQR)
77 (45–150) 80 (4
Time from study medication to angiography, min,
median (IQR) (n  1,140)
55 (43–70) 55 (4
Angiographic characteristics
Angiography performed 1,377/1,398 (98.5%) 681/689 (9
TIMI flow grade 3 before PCI 266/1,270 (20.9%) 123/634 (1
IRV
LAD 540/1,294 (41.7%) 265/640 (4
RCX 156/1,294 (12.1%) 74/640 (1
RCA 579/1,294 (44.7%) 290/640 (4
Graft 13/1,294 (1.0%) 8/640 (1
Left main 6/1,294 (0.5%) 3/640 (0
PCI performed 1,213/1,395 (87.0%) 605/689 (8
PCI immediately after CAG 1,203/1,213 (99.2%) 601/605 (9
Stent placement 1,084/1,208 (89.7%) 541/603 (8
Drug-eluting stent 286/1,083 (26.4%) 131/541 (2
Bare-metal stent 812/1,083 (75.0%) 415/541 (7
Stent length 24.0 12.0 23.5
Stent diameter 3.3 0.4 3.3
ata presented as mean  SD or n (%), unless otherwise indicated.
BMI body mass index; CABG coronary artery bypass grafting; CAG coronary angiography;
olus dose; IQR interquartile range; IRV infarct-related vessel; LAD left anterior descending a
CX  ramus circumflexus; SO  symptom onset; TIMI  Thrombolysis In Myocardial Infarction;asis, 709 patients were randomized to HBD tirofiban and t89 patients to placebo/no tirofiban infusion. There were
lso no relevant differences in baseline clinical or angio-
raphic characteristics between the patients allocated to
BD tirofiban treatment and the patients allocated to
lacebo/no tirofiban infusion (Table 1). Ninety-six percent
f the patients were included and randomized after pre-
ospital infarct diagnosis in the ambulance. The median
ime of diagnosis was 77 min (interquartile range [IQR] 45
an HBD Tirofiban
(n  709) p Value
Double-Blind Phase
(n  984)
Open-Label Phase
(n  414) p Value
61.6 11.9 0.529 61.8 11.9 61.8 12.3 0.930
543/709 (76.6%) 0.625 746/984 (75.8%) 317/414 (76.6%) 0.762
26.9 3.7 0.471 26.8 3.7 26.9 3.9 0.941
319/697 (45.8%) 0.269 459/976 (47.0%) 190/398 (47.7%) 0.811
268/624 (42.9%) 0.973 367/867 (42.3%) 167/375 (44.5%) 0.471
83/707 (11.7%) 0.510 113/983 (11.5%) 43/411 (10.5%) 0.577
239/707 (33.8%) 0.829 336/984 (34.1%) 139/410 (33.9%) 0.930
186/705 (26.4%) 0.545 264/982 (26.9%) 93/408 (22.8%) 0.112
279/690 (40.4%) 0.732 376/970 (38.8%) 169/393 (43.0%) 0.148
63/704 (8.9%) 0.892 83/981 (8.5%) 43/411 (10.5%) 0.235
63/707 (8.9%) 0.257 87/984 (8.8%) 26/412 (6.3%) 0.114
12/707 (1.7%) 0.313 17/984 (1.7%) 12/412 (2.9%) 0.157
10/706 (1.4%) 0.626 17/983 (1.7%) 5/412 (1.2%) 0.481
113/662 (17.1%) 0.487 143/959 (14.9%) 69/336 (20.5%) 0.016
677/709 (95.5%) 0.258 936/984 (95.1%) 407/414 (98.3%) 0.005
132.3 24.2 0.451 131.4 24.3 132.8 25.0 0.303
78.2 15.4 0.585 77.0 14.9 80.0 16.5 0.001
74.9 16.9 0.787 75.1 17.5 74.5 17.5 0.440
76/693 (11.0%) 0.107 119/965 (12.3%) 50/400 (12.5%) 0.931
14.6 9.1 0.645 14.4 9.1 14.4 8.3 0.578
41/709 (5.8%) 0.985 60/984 (6.1%) 21/414 (5.1%) 0.454
25 (12–41) 0.931 25 (12–41)
7) 166 (128–239) 0.636 166 (127–249) 166 (129–242) 0.856
) 74 (44–145) 0.295 77 (45–150) 77 (47–149) 0.797
55 (44–70) 0.589 55 (43–70) 55 (45–72) 0.539
696/709 (98.2%) 0.301 970/984 (98.6%) 407/414 (98.3%) 0.707
143/636 (22.5%) 0.177 185/899 (20.6%) 81/371 (21.8%) 0.617
275/654 (42.0%) 0.815 378/907 (41.7%) 162/387 (41.9%) 0.951
82/654 (12.5%) 0.590 104/907 (11.5%) 52/387 (13.4%) 0.319
289/654 (44.2%) 0.685 415/907 (45.8%) 164/387 (42.4%) 0.263
5/654 (0.8%) 0.381 7/907 (0.8%) 6/387 (1.6%) 0.226
3/654 (0.5%) 1.000 3/907 (0.3%) 3/387 (0.8%) 0.372
608/706 (86.1%) 0.349 861/981 (87.8%) 352/414 (85.0%) 0.165
602/608 (99.0%) 0.531 855/861 (99.3%) 348/352 (98.9%) 0.442
543/605 (89.8%) 0.984 770/855 (90.1%) 314/353 (89.0%) 0.564
155/542 (28.6%) 0.102 182/770 (23.6%) 104/313 (33.2%) 0.001
397/542 (73.2%) 0.188 596/770 (77.4%) 216/313 (69.0%) 0.004
24.5 13.4 0.876 23.8 12.3 24.4 11.2 0.019
3.3 0.4 0.380 3.3 0.5 3.3 0.4 0.540
erebrovascular accident; ECG electrocardiogram; GFR glomerular filtration rate; HBD high
Imyocardial infarction; PCI percutaneous coronary intervention; RCA right coronary artery;
target vessel revascularization.Tirofib
89)
12.1
5.5%)
3.9
8.7%)
3.0%)
0.6%)
4.4%)
5.0%)
9.5%)
.2%)
.3%)
.5%)
.7%)
5.6%)
6.7%)
24.9
15.5
18.1
3.8%)
8.6
.8%)
2–41)
28–25
6–151
3–70)
8.8%)
9.4%)
1.4%)
1.6%)
5.3%)
.3%)
.5%)
7.8%)
9.3%)
9.7%)
4.2%)
6.7%)
10.3
0.5
CVA co 150 min) after the onset of symptoms. The time intervals
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High-Dose Tirofiban in STEMI June 1, 2010:2446–55re shown in Figure 2. The median duration of transport to
he nearest PCI center was 33 min (IQR 19 to 49 min).
cute angiography was performed in 98.5% of the patients
t a median time interval of 20 min (IQR 10 to 33 min)
fter arrival at the PCI center. The median total ischemic
ime was 166 min (IQR 128 to 246 min), whereas the
edian duration of treatment with tirofiban or placebo/no
irofiban infusion until angiography was 55 min (IQR 44 to
0 min). There were 81 patients (5.8%) who had a false-
ositive STEMI diagnosis, evenly distributed between the
irofiban and placebo/no tirofiban infusion groups. Five
atients died before angiography could be performed, and
6 patients did not undergo angiography because of a clearly
alse-positive diagnosis on arrival at the hospital. The
lectrocardiographic and Clinical Outcome in the 2 Study Phases*Table 2 Electrocardiographic and Clinical Outcome in the 2 Stu
Double-B
(n 
Residual ST-segment deviation 3 mm 377/90
Cumulative ST-segment deviation 1 h post-PCI, mm 4.2
ST-segment resolution 1-h post-PCI
Complete 550/87
Partial 204/87
No 122/87
30 days
Death, re-MI, or urgent TVR 72/95
Death 30/95
Recurrent MI 27/95
Urgent TVR 38/95
Urgent PCI 30/95
Urgent CABG 8/95
1 year
Death 41/93
Cardiac death 32/93
Noncardiac death 9/93
Placebo
(n  493)
H
Residual ST-segment deviation 3 mm 205/455 (45.1%) 17
Cumulative ST-segment deviation 1-h post-PCI, mm 4.8 6.3
ST-segment resolution 1 h post-PCI
Complete 264/440 (60.0%) 28
Partial 104/440 (23.6%) 10
No 72/440 (16.4%) 5
30 days
Death, re-MI, or urgent TVR 39/477 (8.2%) 3
Death 19/477 (4.0%) 1
Recurrent MI 14/477 (2.9%) 1
Urgent TVR 20/477 (4.2%) 1
Urgent PCI 19/477 (4.0%) 1
Urgent CABG 1/477 (0.2%)
1 year
Death 25/470 (5.3%) 1
Cardiac death 20/470 (4.3%) 1
Noncardiac death 5/470 (1.1%)
ata presented as mean  SD or n (%), unless otherwise noted. *In 17 patients (double-blind ph
double-blind phase) and 3 patients (open-label phase), follow-up at 1 year was known, but not at
Abbreviations as in Table 1.ngiographic characteristics are shown in Table 1. Initial wIMI flow grade 3 of the infarct-related artery was present
n 22.5% of patients in the tirofiban group versus 19.4% in
he placebo/no tirofiban infusion group (p  0.177).
ighty-seven percent of the patients received PCI, after
hich distal embolization was present in 5.2% of the
irofiban group and in 7.4% of the placebo/no tirofiban
nfusion group (p  0.170).
0-day outcome. The 30-day follow-up data were com-
lete for 1,339 patients (96%). Fifty patients (3.6%) were
nwilling to give written informed consent even though
hey had given oral informed consent in the ambulance, and
patients (0.6%) were lost to follow-up. All clinical
utcome- and safety-associated parameters are described in
able 3. The incidence of the composite primary end point
hases*
hase Open Label Phase
(n  414) p Value
6%) 154/364 (42.3%) 0.820
4.2 6.0 0.912
8%) 222/356 (62.4%) 0.899
3%) 88/356 (24.7%)
9%) 46/356 (12.9%)
%) 24/389 (6.2%) 0.364
%) 12/389 (3.1%) 0.944
%) 1/389 (0.3%) 0.003
%) 13/389 (3.3%) 0.568
%) 10/389 (2.6%) 0.567
%) 3/389 (0.8%) 0.999
%) 22/389 (5.7%) 0.319
%) 14/389 (3.6%) 0.868
%) 8/389 (2.1%) 0.114
rofiban
491) p Value
No Tirofiban
(n  196)
HBD Tirofiban
(n  218) p Value
(38.1%) 0.035 77/172 (44.8%) 77/192 (40.1%) 0.369
4.6 0.003 4.6 5.4 3.9 6.5 0.097
(65.6%) 0.033 96/167 (57.5%) 126/189 (66.7%) 0.006
(22.9%) 39/167 (23.4%) 49/189 (25.9%)
(11.5%) 32/167 (19.2%) 14/189 (7.4%)
(7.0%) 0.485 18/185 (9.7%) 6/204 (2.9%) 0.005
(2.3%) 0.144 8/185 (4.3%) 4/204 (2.0%) 0.178
(2.7%) 0.863 1/185 (0.5%) 0/204 (0.0%) 0.476
(3.8%) 0.761 11/185 (5.9%) 2/204 (1.0%) 0.007
(2.3%) 0.144 9/185 (4.9%) 1/204 (0.5%) 0.008
(1.5%) 0.038 2/185 (1.1%) 1/204 (0.5%) 0.607
(3.4%) 0.157 13/186 (7.0%) 9/203 (4.4%) 0.276
(2.6%) 0.155 9/186 (4.8%) 5/203 (2.5%) 0.209
(0.9%) 0.999 4/186 (2.2%) 4/203 (2.0%) 0.999
d 3 patients (open-label phase), follow-up at 30 days was known, but not at 1 year; in 4 patients
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June 1, 2010:2446–55 High-Dose Tirofiban in STEMIlacebo/no tirofiban infusion group (odds ratio [OR]: 0.65;
5% confidence interval [CI]: 0.43 to 0.99, p  0.043).
otal mortality was 2.2% in the tirofiban group compared
ith 4.1% in the placebo/no tirofiban infusion group (OR:
.53; 95% CI: 0.28 to 1.01, p  0.051), and the incidence
f major bleeding was 3.4% in the tirofiban group and 2.9%
n the placebo/no tirofiban infusion group (OR: 1.19; 95%
I: 0.64 to 2.21, p  0.58). Stroke occurred significantly
Figure 2 Median Time Intervals From Symptom Onset to Reper
and in the Patients Randomized in the Ambulance or
The large majority of patients (96%) were randomized in the ambulance at a media
associated with a longer ischemic time, mainly due to a longer time to diagnosis (120
Clinical Outcome and Safety-Related ParameterTable 3 Clinical Outcome and Safety-Relate
Placebo/No T
30 days (n 
Death, re-MI, or urgent TVR 57 (8
Death 27 (4
Recurrent MI 15 (2
Urgent TVR 31 (4
Urgent PCI 28 (4
Urgent CABG 3 (0
Major bleeding 19 (2
Major CABG-related 8 (1
Major non–CABG-related 11 (1
Minor bleeding 29 (4
Minor CABG-related 10 (1
Minor non–CABG-related 19 (2
Stroke within 30 days 9 (1
Net clinical outcome* 77 (1
1 year (n 
Death 38 (5
Cardiac death 29 (4
Noncardiac death 9 (1Data presented as n (%). *The combined incidence of death, re-MI, urgent TV
Abbreviations as in Table 1.ess often in patients pre-treated tirofiban (0.3% vs. 1.4%,
R: 0.215; 95% CI: 0.046 to 0.999, p  0.03). Kaplan-
eier curves for survival free from MACE are shown in
igure 3.
ubgroup analysis. Figure 4 shows the OR and 95% CI
or the incidence of MACE in each of the pre-specified
ubgroups of patients and in the patients who underwent
PCI (post-hoc analysis). In patients who presented early
n (Balloon Inflation) in the Total Population
on-Percutaneous Coronary Intervention Referral Center
5 min after symptom onset. Randomization at a referral center was
Angio  angiography; IQR  interquartile range.
ameters
n Infusion Tirofiban p Value
(n  677)
39 (5.8%) 0.043
15 (2.2%) 0.051
13 (1.9%) 0.659
20 (3.0%) 0.098
12 (1.8%) 0.008
8 (1.2%) 0.140
23 (3.4%) 0.580
11 (1.6%) 0.520
12 (1.8%) 0.876
40 (5.9%) 0.206
12 (1.8%) 0.706
28 (4.1%) 0.208
2 (0.3%) 0.031
54 (8.0%) 0.024
(n  670)
25 (3.7%) 0.078
17 (2.5%) 0.061
8 (1.2%) 0.773fusio
in a N
n of 7
min).sd Par
irofiba
662)
.6%)
.1%)
.3%)
.7%)
.2%)
.5%)
.9%)
.2%)
.7%)
.4%)
.5%)
.9%)
.4%)
1.6%)
656)
.8%)
.4%)
.4%)R, stroke, or major bleeding.
a
d
g
v
w
9
i
c
0
f
w
p
i
b
T
1
f
o
F
f
c
i
c
7
c
0
m
t
o
e
p
6
p
w
t
(
D
T
s
a
c
c
l
T
t
w
O
i
s
a
s
t
p
S
2452 ten Berg et al. JACC Vol. 55, No. 22, 2010
High-Dose Tirofiban in STEMI June 1, 2010:2446–55fter the onset of symptoms (time from symptom onset until
iagnosis 75 min, which is the median in the follow-up
roup), initial TIMI flow grade 3 of the infarct-related
essel was present in 27.4% the tirofiban group compared
ith 19.4% in the placebo/no tirofiban group (OR: 1.57;
5% CI: 1.07 to 2.30). In this group of early presenters, the
ncidence of MACE was 4.3% in the tirofiban group
ompared with 8.1% in the placebo/no tirofiban group (OR:
.51; 95% CI: 0.26 to 0.99). The Breslow-Day test for time
rom symptom onset until diagnosis (75 min or75 min)
as not significant (p  0.216). In patients who underwent
PCI (n 1,203, 86%), the incidence of MACEs was 4.5%
n the tirofiban group compared with 8.5% in the place-
o/no tirofiban group (OR: 0.50; 95% CI: 0.31 to 0.82).
he Breslow-Day test for pPCI was significant (p 0.035).
-year outcome. The 1-year follow-up data were available
or 1,326 of 1,398 patients (94.8%): 94.0% from the
pen-label phase and 95.2% from the double-blind phase.
or a total of 72 patients (5.2%), there were no 1-year
ollow-up data for the following reasons: decision of physi-
ian (n  1), lost to follow-up (n  11), no written
nformed consent (n  43) or withdrawal of informed
onsent (n  17). The mean follow-up duration was 361 
6 days. Total mortality was 3.7% in the tirofiban group
ompared with 5.8% in the placebo/no tirofiban group (OR:
.63; 95% CI: 0.38 to 1.06, p  0.08) (Fig. 5A). Total
ortality was lower in the pre-specified subgroup of pa-
ients who received HBD tirofiban within 75 min after the
Figure 3 Kaplan-Meier Survival Curves Free From Major Advers
1,339 Patients From the Open-Label and Blinded Stud
Log-rank testing gave a value of 0.040 representing a significant difference in evenset of symptoms (1.8% vs. 4.3%, p  0.059), whereas the affect on long-term mortality was less evident for patients
re-treated 75 min after the onset of symptoms (5.7% vs.
.2%, p  0.803). Post hoc analysis in the subgroup of
atients who underwent pPCI showed that 1-year mortality
as significantly lower in the HBD tirofiban group than in
he placebo/no tirofiban group (2.4% vs. 5.5%, p  0.007)
Fig. 5B).
iscussion
his pooled analysis of the 2 phases of the On-TIME 2 trial
howed that early initiation of HBD tirofiban, in addition to
spirin, heparin, and high-dose clopidogrel, improved the
linical outcome at the 30-day follow-up, with no signifi-
ant increase in major bleeding. The strong trend toward a
ower mortality rate was maintained at the 1-year follow-up.
he effect was more evident in patients who received HBD
irofiban early after the onset of symptoms and in patients
ho underwent pPCI.
In the randomized, double-blind, placebo-controlled
n-TIME 2 trial, we demonstrated that the early admin-
stration of HBD tirofiban in the ambulance resulted in a
ignificantly better ST-segment resolution, both before and
fter pPCI (9). This represents a better myocardial perfu-
ion with a GP IIb/IIIa blocker. With the pooled analysis of
he 2 study phases, we were also able to show an effect of
re-hospital HBD tirofiban on clinical outcome. The worse
T-segment resolution in the placebo or no HBD tirofiban
diac Events in the Group of
ases Who Had 30-Day Follow-Up
survival between tirofiban and placebo or no tirofiban pre-treated patients.e Car
y Ph
nt-freerm might be a reflection of insufficient inhibition of
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June 1, 2010:2446–55 High-Dose Tirofiban in STEMIlatelet aggregation with aspirin and clopidogrel alone,
hich was shown in our previous work that found the
imited inhibition of platelet aggregation during the first
ours, when platelet activation is highest, in patients with
TEMI (12).
The On-TIME 2 trial shows that especially mortality and
rgent PCI were reduced by early initiation of tirofiban.
he reduction in mortality is probably related to the
mproved myocardial reperfusion. Urgent target vessel re-
ascularization was reduced mainly through a lower rate of
tent thrombosis, which again may affect mortality (13).
The beneficial effects of tirofiban on MACEs after 30
ays and on mortality were stronger for patients with a brief
75 min) duration of symptoms before diagnosis and for
atients who underwent pPCI. The number needed to treat
NNT) in the subgroup of early presenters was 26, and in
he subgroup of patients with a longer period from symptom
nset until diagnosis (75 min), it was 113. The fact that
he early presenters, in particular, have more benefit from
arly tirofiban treatment is probably due to the lytic effects
Figure 4 Odds Ratios and 95% Confidence Intervals for the Inc
Pre-Specified Subgroups of Patients and in the Patien
In the total population, the relative reduction in major adverse cardiac events (MA
patients who were pre-treated very shortly after the onset of symptoms (75 min)
Day test was significant (p  0.035), suggesting an interaction between early pre-
other abbreviations as in Figures 1 and 2.f GP IIb/IIIa inhibitors on fresh thrombi. Patients who Aeceived tirofiban within 75 min after symptom onset had a
ignificantly higher initial TIMI flow grade 3 (27.4% vs.
9.4%, p  0.02). Therefore, every effort should be made to
dminister the medication as soon as possible in the ambu-
ance at the first contact with the patient. This pre-hospital
dministration of medication differs from the procedure
n most other trials in which medication was started in
he hospital. In our trial, the median time from the onset
f symptoms until the initiation of the medication was
nly 90 min (Fig. 2). This compares favorably with other
TEMI trials, such as the BRAVE-3 (Bavarian Reperfusion
lternatiVes Evaluation) study and the FINESSE (Facili-
ated Intervention With Enhanced Reperfusion Speed to
top Events) trial, in which GP IIb/IIIa blockers were
tarted a mean of 200 and 165 min, respectively, after the
nset of symptoms (14,15). In the BRAVE-3 trial, the GP
Ib/IIIa blocker abciximab did not improve myocardial
alvage, which probably demonstrates that after a mean of
00 min, organized thrombi do not lyse after the adminis-
ration of GP IIb/IIIa blockers (14). The results of the
e of MACE in the
ho Underwent Primary PCI (Post-Hoc Analysis)
s 35%. The relative risk reduction was considerably higher in male patients, in
n patients who actually underwent primary PCI. In the latter group, the Breslow-
ent with tirofiban and primary PCI. TIMI  Thrombolysis In Myocardial Infarction;idenc
ts W
CE) wa
, and i
treatmDMIRAL (Abciximab Before Direct Angioplasty and
S
L
a
c
i
t
t
2454 ten Berg et al. JACC Vol. 55, No. 22, 2010
High-Dose Tirofiban in STEMI June 1, 2010:2446–55tenting in Myocardial Infarction Regarding Acute and
ong-term Follow-up) study, in which patients received
bciximab in the ambulance well in advance of arrival at the
Figure 5 Kaplan-Meier 1-Year Survival Curves for the Total Pop
1-Year Follow-Up and for the 1,155 Patients With 1-Y
Log-rank testing gave a value of 0.077, representing a nonsignificant difference in
intention-to-treat cohort, whereas log-rank testing gave a p value of 0.007, represe
pre-treated patients who actually underwent primary percutaneous coronary interve
(B) Post-hoc analysis, primary PCI group.atheterization laboratory, are consistent with our findings nn showing a greater benefit for patients who received early
reatment after the onset of symptoms (16). The observa-
ional report of a well-organized STEMI hub-and-spoke
n of 1,326 Patients With
ollow-Up Who Underwent Primary PCI
al between tirofiban and placebo or no tirofiban pre-treated patients in the
a significant difference in survival between tirofiban and placebo or no tirofiban
(PCI). (A) Intention-to-treat (ITT) analysis for 1,326 patients with 1-year follow-up.ulatio
ear F
surviv
nting
ntionetwork shows a clear advantage of early administration of
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June 1, 2010:2446–55 High-Dose Tirofiban in STEMIP IIb/IIIa blockers in a spoke center emergency department
r during ambulance transfer (n  380; pain to GP IIb/IIIa
gents: mean 126 min) compared with delayed (in the cathe-
erization laboratory) administration (n  744; pain to GP
Ib/IIIa agents: mean 169 min) (17). Our findings are in
greement with the results of thrombolytic therapy for patients
ith STEMI, the efficacy of which is also highest within the
o-called golden hour after the onset of symptoms.
tudy limitations. In the present study, we pooled the
esults from the double-blind study phase with 414 patients
rom the open-label phase who were randomized to HBD
irofiban or no tirofiban in the ambulance. The purpose of
his open-label phase was to gain experience in recruiting
atients for a randomized clinical trial in the ambulance,
ithout the involvement of a physician. Although the
reatment in the open-label phase was not blinded, it is
mportant to note that the study protocol for the 2 phases
nly differed with regard to trial design: open-label versus
linded. The pooled analysis was pre-specified in the final
rotocol and statistical plan for the study, and there was no
ifference in baseline characteristics or in the effect of HBD
irofiban on ST-segment resolution between the 2 phases of
he study (Table 2). The fact that the results of the
pen-label study phase are consistent with the results from
he double-blind phase may be interpreted as a proof of
oncept.
onclusions
arly pre-hospital administration of a HBD of tirofiban, in
ddition to aspirin, high-dose clopidogrel and unfraction-
ted heparin, improves the clinical outcome after pPCI in
atients with acute STEMI, with no increased risk of major
leeding. The results emphasize the importance of pre-
ospital infarct diagnosis in the ambulance and subsequent
nitiation of potent antithrombotic therapy very early after
he onset of symptoms.
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APPENDIX
or a list of the members of the On-TIME 2 study group,
lease see the online version of this article.
